Charles River Laboratories International, Inc. Share Price

Equities

CRL

US1598641074

Biotechnology & Medical Research

Market Closed - Nyse 21:10:00 18/06/2025 BST 5-day change 1st Jan Change
145.29 USD +0.17% Intraday chart for Charles River Laboratories International, Inc. -3.85% -21.29%
Capitalization 7.12B 6.19B 5.82B 5.29B 9.75B 616B 10.92B 68.34B 26.41B 282B 26.73B 26.17B 1,030B P/E ratio 2025 *
32.1x
P/E ratio 2026 * 25.1x
Enterprise value 9.29B 8.07B 7.59B 6.9B 12.72B 803B 14.25B 89.14B 34.45B 367B 34.87B 34.13B 1,344B EV / Sales 2025 *
2.38x
EV / Sales 2026 * 2.25x
Free-Float
97.96%
Yield 2025 *
-
Yield 2026 * -
More valuation ratios * Estimated data
Dynamic Chart
1 day+0.17%
1 week-3.85%
Current month+7.12%
1 month+2.77%
3 months-17.89%
6 months-20.68%
Current year-21.29%
More quotes
1 week 143.06
Extreme 143.06
152.64
1 month 132.58
Extreme 132.5828
154.43
Current year 91.86
Extreme 91.8609
193.56
1 year 91.86
Extreme 91.8609
254.15
3 years 91.86
Extreme 91.8609
275
5 years 91.86
Extreme 91.8609
460.21
10 years 59.99
Extreme 59.99
460.21
More quotes
Manager TitleAgeSince
Chief Executive Officer 74 31/12/1991
Director of Finance/CFO 52 30/04/2022
Chief Operating Officer 55 10/11/2021
Director TitleAgeSince
Chairman 74 31/12/1999
Director/Board Member 68 04/07/2017
Director/Board Member 69 30/09/2019
More insiders
Change 5d. change 1-year change 3-years change Capi.($)
+0.17%-3.85%-30.75%-30.34% 7.12B
-0.04%-2.95%+18.36%+12.55% 48.55B
-18.96%+285.80%+58,645.35%+5,665.23% 38.57B
+0.33%-2.66%-27.36%-22.22% 26.66B
+0.31%+0.06%-1.43%+20.47% 26.1B
-0.23%+2.86%+14.98%-17.84% 12.55B
-1.48%-2.41%+127.74% - 12.14B
+1.11%-1.45%-54.99%-30.13% 11.27B
-1.27%-0.59%+38.57%+99.66% 10.44B
0.00%-0.36%+3.44%+1.29% 10.08B
Average -2.14%+37.84%+5,873.39%+633.19% 20.35B
Weighted average by Cap. -3.90%+71.43%+11,122.82%+1,146.21%
See all sector performances

Financials

2025 *2026 *
Net sales 3.9B 3.38B 3.18B 2.89B 5.33B 337B 5.98B 37.39B 14.45B 154B 14.63B 14.32B 564B 3.97B 3.44B 3.24B 2.94B 5.43B 343B 6.08B 38.05B 14.71B 157B 14.89B 14.57B 574B
Net income 219M 190M 179M 163M 300M 18.96B 336M 2.1B 813M 8.67B 823M 806M 31.73B 273M 237M 223M 202M 373M 23.58B 418M 2.62B 1.01B 10.78B 1.02B 1B 39.45B
Net Debt 2.17B 1.88B 1.77B 1.61B 2.97B 187B 3.33B 20.8B 8.04B 85.73B 8.14B 7.96B 314B 1.79B 1.56B 1.46B 1.33B 2.45B 155B 2.75B 17.19B 6.64B 70.85B 6.72B 6.58B 259B
More financial data * Estimated data
Logo Charles River Laboratories International, Inc.
Charles River Laboratories International, Inc. specializes in the development of products and services in the field of research and non-clinical drug development for pharmaceutical companies, government agencies and academic institutions. Net sales break down by activity as follows: - discovery and safety assessment services (60.5%): discovery services for the identification, screening and selection of main compounds for the development of new drug candidates, and in vivo and in vitro testing, including pharmacokinetic, bioanalytical, metabolic, toxicological and pathological studies, for the safety assessment of pharmaceutical products, medical devices, animal health products, chemical and agrochemical products and biocides; - development and sale of research models and related services (20.5%): mice, rats, immunodeficient models, rabbits, guinea pigs, hamsters, etc. The group also offers primary cells and specialized products (bioconservation products, freezing media for cell cultures, antigens, peptides, humanized mouse models, etc.) for the development and manufacture of new cell therapies ; - development of solutions used in drug manufacturing processes (19%): products and services for microbiological testing, in vitro testing, endotoxin testing, microbial identification, development, manufacturing of avian vaccines, etc. The group also offers contract manufacturing services for cell and gene therapies. Net sales break down by source of income between sales of services (81.6%) and sales of products (18.4%). Net sales are distributed geographically as follows: the United States (55.3 Europe (26.6%), Canada (11.9%), Asia/Pacific (4.9%) and other (1.3%).
Employees
19,400
More about the company
Date Price Change Volume
18/06/25 145.29 $ +0.17% 632,963
17/06/25 145.05 $ -3.96% 979,244
16/06/25 151.03 $ +1.06% 823,542
13/06/25 149.45 $ -1.61% 699,376
12/06/25 151.89 $ +0.52% 910,588

Delayed Quote Nyse, June 18, 2025 at 09:10 pm

More quotes
Trading Rating
Investor Rating
ESG MSCI
A
More Ratings
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
19
Last Close Price
145.05USD
Average target price
156.14USD
Spread / Average Target
+7.65%
Consensus

Quarterly revenue - Rate of surprise